Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive summary

Stroke

Volumn 36, Issue 9, 2005, Pages 2049-2056

  Bates, Barbara ^a   Choi, John Y ^a   Duncan, Pamela W ^a   Glasberg, Jonathan J ^a   Graham, Glenn D ^a   Katz, Richard C ^a   Lamberty, Kerri ^a   Reker, Dean ^a   Zorowitz, Richard ^a  

^a NONE

Author keywords

AHA ASA Endorsed Practice Guidelines; Quality of life; Rehabilitation; Stroke

Indexed keywords

ALCOHOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CENTRAL DEPRESSANT AGENT; CLONIDINE; DANTROLENE; DIAZEPAM; FLUOXETINE; LEVODOPA; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; PHENOL; PRAZOSIN; SEROTONIN UPTAKE INHIBITOR; THREO 3,4 DIHYDROXYPHENYLSERINE; TIZANIDINE;

ADULT; CAREGIVER; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DORSAL RHIZOTOMY; DRUG USE; DYSPHAGIA; EARLY DIAGNOSIS; EVALUATION; EVIDENCE BASED MEDICINE; FAMILY; HUMAN; LANGUAGE ABILITY; MEDICAL EXPERT; MEDICAL LITERATURE; MENTAL INSTABILITY; MUSCLE TRAINING; MUSCLE WEAKNESS; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLYSIS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RATING SCALE; RECURRENT DISEASE; REVIEW; SCREENING TEST; SECONDARY PREVENTION; SHOULDER PAIN; SPASTICITY; SPEECH DISORDER; STROKE; SWALLOWING; TREATMENT OUTCOME; UNITED STATES; VEIN THROMBOSIS;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; DELIVERY OF HEALTH CARE; HEALTH PLANNING GUIDELINES; HEALTH SERVICES; HOSPITAL DEPARTMENTS; HOSPITALS, SPECIAL; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES; REHABILITATION;

EID: 24644443200     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000180432.73724.AD     Document Type: Review

References (126)

1. Gresham GE, Duncan PW, Stason WB, et al. Post-Stroke Rehabilitation. Clinical Practice Guideline, No. 16. Rockville, Md: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; May 1995. AHCPR Publication No. 95-0662.
2. Royal College of Physicians. National Clinical Guidelines for Stroke. 2nd ed. Prepared by the Intercollegiate Stroke Working Party. London: Royal College of Physicians; 2004. Available at: http://www.rcplondon.ac.uk/pubs/books/ stroke/index.htm. Accessed July 20, 2005.
3. Scottish Intercollegiate Guidelines Network (SIGN). Management of Patients with Stroke Part III: Identification and Management of Dysphagia, No. 20. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network; 1997. [Superseded by Management of Patients with Stroke: Identification and Management of Dysphagia, No. 78; 2004.]
4. United States Preventive Service Task Force (USPSTF). Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams and Wilkins; 1996.
5. American Heart Association. Heart and Stroke Statistical Update-2000. Dallas, Tex: American Heart Association; 1999.
6. Cifu DX, Stewart DG. Factors affecting functional outcome after stroke: a critical review of rehabilitation interventions. Arch Phys Med Rehabil. 1999;80(5 suppl 1):S35-S39.
7. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev. 2002(1):CD000197.
8. Evans RL, Connis RT, Hendricks RD, Haselkorn JK. Multidisciplinary rehabilitation versus medical care: a meta-analysis. Soc Sci Med. 1995; 40:1699-1706.
9. Duncan PW, Horner RD, Reker DM, Samsa GP, Hoenig H, Hamilton B, LaClair BJ, Dudley TK. Adherence to postacute rehabilitation guidelines is associated with functional recovery in stroke. Stroke. 2002; 33:167-177.
10. Duncan PW, Lai SM, van Culin V, Huang L, Clausen D, Wallace D. Development of a comprehensive assessment toolbox for stroke. Clin Geriatr Med. 1999;15:885-915.
11. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, Spence JD. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1998;339:1415-1425.
12. Albers GW, Amareneo P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119(1 suppl): 300S-320S.
13. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
14. Albers GW. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients? Neurology. 2000;54:1022-1028.
15. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(suppl 3):483S-512S.
16. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(suppl 3):338S-400S.
17. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Stroke. 1998;29:1389-1392.
18. European Stroke Prevention Study. ESPS Group. Stroke. 1990;21: 1122-1130.
19. Bellavance A. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study. Stroke. 1993;24:1452-1457.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
21. [Errata in N Engl J Med. 2000;342:1376;
22. N Engl J Med. 2000;342:748.]
23. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
24. [Errata in N Engl J Med. 2001;345:1716;
25. N Engl J Med. 2001;345:1506.]
26. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancer. 2002;359:995-1003.
27. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-1041.
28. [Errata in: Lancet. 2001:358:1556;
29. Lancet. 2002:359: 2120.
30. ] 24. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
31. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
32. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134:931-940.
33. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
34. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. 2001;103:163-182.
35. Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, Kelly-Hayes M, Sacco RL, Whisnant JP. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 1999;30:1991-1994.
36. Reding MJ, Potes E. Rehabilitation outcome following initial unilateral hemispheric stroke: life table analysis approach. Stroke. 1988;19: 1354-1358.
37. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569-1581.
38. Bath PM, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke. 2000;31:1770-1778.
39. Bath PM, Bath FJ, Smithard DG. Interventions for dysphagia in acute stroke. Cochrane Database Syst Rev. 2000;(2):CD000323.
40. Bijsterveld NR, Hettiarachchi R, Peters R, Prins MH, Levi M, Buller HR. Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost. 1999;82 suppl 1:139-147.
41. Kamran SI, Downey D, Ruff RL. Pneumatic sequential compression reduces the risk of deep vein thrombosis in stroke patients. Neurology. 1998;50:1683-1688.
42. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation. 2004;110:e454-e458.
43. Berlowitz DR, Brandeis GH, Anderson JJ, Ash AS, Kader B, Morris JN, Moskowitz MA. Evaluation of a risk-adjustment model for pressure ulcer development using the Minimum Data Set. J Am Geriatr Soc. 2001;49:872-876.
44. Berlowitz DR, Brandeis GH, Morris JN, Ash AS, Anderson JJ, Kader B, Moskowitz MA. Deriving a risk-adjustment model for pressure ulcer development using the Minimum Data Set. J Am Geriatr Soc. 2001;49: 866-871.
45. Sussman C, Bates-Jensen BM, eds. Wound Care: A Collaborative Practice Manual for Physical Therapists and Nurses. Gaithersburg, Md: Aspen Publishers; 1998.
46. Nakayama H, Jorgensen HS, Pedersen PM, Raaschou HO, Olsen TS. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. Stroke. 1997;28:58-62.
47. Venn MR, Taft L, Carpentier B, Applebaugh G. The influence of timing and suppository use on efficiency and effectiveness of bowel training after a stroke. Rehabil Nurs. 1992;17:116-120.
48. Evans A, Perez I, Harraf F, Melbourn A, Steadman J, Donaldson N, Kalra L. Can differences in management processes explain different outcomes between stroke unit and stroke-team care? Lancet. 2001;358: 1586-1592.
49. Langhorne P, Duncan P. Does the organization of postacute stroke care really matter? Stroke. 2001;32:268-274.
50. Early Supported Discharge Trialists. Services for reducing duration of hospital care for acute stroek patients (Cochrane Review). The Cochrane Library. Issue 4. Oxford, UK: Update Software; 2001.
51. Rudd AG, Wolfe CD, Tilling K, Beech R. Randomised controlled trial to evaluate early discharge scheme for patients with stroke. BMJ. 1997; 315:1039-1044.
52. [Erratum in: BMJ. 1998;316:435.]
53. Indredavik B, Slordahl SA, Bakke F, Rokseth R, Haheim LL. Stroke unit treatment. Long-term effects. Stroke. 1997;28:1861-1866.
54. Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Stroke unit treatment improves long-term quality of life: a randomized controlled trial. Stroke. 1998;29:895-899.
55. Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Stroke unit treatment: 10-year follow-up. Stroke. 1999;30:1524-1527.
56. Kalra L, Evans A, Perez I, Knapp M, Donaldson N, Swift CG. Alternative strategies for stroke care: a prospective randomised controlled trial. Lancet. 2000;356:894-899.
57. Langhorne P, Wagenaar R, Partridge C. Physiotherapy after stroke: more is better? Physiother Res Int. 1996;1:75-88.
58. Kwakkel G, Wagenaar RC, Twisk JW, Lankhorst GJ, Koetsier JC. Intensity of leg and arm training after primary middle-cerebral-artery stroke: a randomised trial. Lancet. 1999;354:191-196.
59. Finestone HM, Foley NC, Woodbury MG, Greene-Finestone L. Quantifying fluid intake in dysphagic stroke patients: a preliminary comparison of oral and nonoral strategies. Arch Phys Med Rehabil. 2001; 82:1744-1746.
60. Martin-Harris B, Logemann JA, McMahon S, Schleicher M, Sandidge J. Clinical utility of the modified barium swallow. Dysphagia. 2000;15: 136-141.
61. Rasley A, Logemann JA, Kahrilas PJ, Rademaker AW, Pauloski BR, Dodds WJ. Prevention of barium aspiration during videofluoroscopic swallowing studies: value of change in posture. AJR Am J Roentgenol. 1993;160:1005-1009.
62. Robey RR. The efficacy of treatment for aphasic persons: a meta-analysis. Brain Lang. 1994;47:582-608.
63. Robey RR. A meta-analysis of clinical outcomes in the treatment of aphasia. J Speech Lang Hear Res. 1998;41:172-187.
64. Whurr R, Lorch MP, Nye C. A meta-analysis of studies carried out between 1946 and 1988 concerned with the efficacy of speech and language therapy treatment for aphasic patients. Eur J Disord Commun. 1992;27:1-17.
65. Whurr R, Lorch MP, Nye C. Efficacy of speech and language therapy for aphasia: a meta-analytic review. Neurol Rev Int. 1997;1:7-11.
66. Elman RJ, Bernstein-Ellis E. The efficacy of group communication treatment in adults with chronic aphasia. J Speech Lang Hear Res. 1999;42:411-419.
67. Katz RC, Wertz RT. The efficacy of computer-provided reading treatment for chronic aphasic adults. J Speech Lang Hear Res. 1997;40: 493-507.
68. Wertz RT, Weiss DG, Aten JL, Brookshire RH, Garcia-Bunuel L, Holland AL, Kurtzke JF, LaPointe LL, Milianti FJ, Brannegan R, et al. Comparison of clinic, home, and deferred language treatment for aphasia: a Veterans Administration Cooperative Study. Arch Neurol. 1986;43:653-658.
69. Bohannon RW, Walsh S. Nature, reliability, and predictive value of muscle performance measures in patients with hemiparesis following stroke. Arch Phys Med Rehabil. 1992;73:721-725.
70. Andrews AW, Bohannon RW. Discharge function and length of stay for patients with stroke are predicted by lower extremity muscle force on admission to rehabilitation. Neurorehabil Neural Repair. 2001;15: 93-97.
71. Visintin M, Barbeau H, Korner-Bitensky N, Mayo NE. A new approach to retrain gait in stroke patients through body weight support and treadmill stimulation. Stroke. 1998;29:1122-1128.
72. Kosak MC, Reding MJ. Comparison of partial body weight-supported treadmill gait training versus aggressive bracing assisted walking post stroke. Neurorehabil Neural Repair. 2000;14:13-19.
73. Dromerick AW, Edwards DF, Hahn M. Does the application of constraint-induced movement therapy during acute rehabilitation reduce arm impairment after ischemic stroke? Stroke. 2000;31:2984-2988.
74. Glanz M, Klawansky S, Stason W, Berkey C, Chalmers TC. Functional electrostimulation in poststroke rehabilitation: a meta-analysis of the randomized controlled trials. Arch Phys Med Rehabil. 1996;77: 549-553.
75. Price CI, Pandyan AD. Electrical stimulation for preventing and treating post-stroke shoulder pain: a systematic Cochrane review. Clin Rehabil. 2001;15:5-19. Review.
76. Bogataj U, Gros N, Kljajic M, Acimovic R, Malezic M. The rehabilitation of gait in patients with hemiplegia: a comparison between conventional therapy and multichannel functional electrical stimulation therapy. Phys Ther. 1995;75:490-502.
77. Gelber DA, Good DC, Dromerick A, Sergay S, Richardson M. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001;32:1841-1846.
78. Ketel WB, Kolb ME. Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function. Curr Med Res Opin. 1984;9:161-169.
79. Milanov IG. Mechanisms of baclofen action on spasticity. Acta Neurol Scand. 1992;85:305-310.
80. Katrak PH, Cole AM, Poulos CJ, McCauley JC. Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehabil. 1992;73:4-9.
81. Pedersen E, Arlien-Soborg P, Mai J. The mode of action of the gaba derivative baclofen in human spasticity. Acta Neurol Scand. 1974;50: 665-680.
82. Goldstein LB. Common drugs influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators. Neurology. 1995;45: 865-871.
83. Goldstein LB. Potential effects of common drugs on stroke recovery. Arch Neurol. 1998;55:454-456.
84. Troisi E, Paolucci S, Silvestrini M, Matteis M, Vernieri F, Grasso MG, Caltagirone C. Prognostic factors in stroke rehabilitation: the possible role of pharmacological treatment. Acta Neurol Scand. 2002;105: 100-106.
85. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306-1310.
86. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;31: 2402-2406.
87. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C; Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395-400.
88. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil. 1998;77: 510-515.
89. Kong KH, Chua KS. Neurolysis of the musculocutaneous nerve with alcohol to treat poststroke elbow flexor spasticity. Arch Phys Med Rehabil. 1999;80:1234-1236.
90. On AY, Kirazli Y, Kismali B, Aksit R. Mechanisms of action of phenol block and botulinus toxin Type A in relieving spasticity: electrophysiologic investigation and follow-up. Am J Phys Med Rehabil. 1999;78: 344-349.
91. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32: 2099-2109.
92. Van Ouwenaller C, Laplace PM, Chantraine A. Painful shoulder in hemiplegia. Arch Phys Med Rehabil. 1986;67:23-26.
93. Cicerone KD, Dahlberg C, Kalmar K, Langenbahn DM, Malec JF, Bergquist TF, Felicetti T, Giacino JT, Harley JP, Harrington DE, Herzog J, Kneipp S, Laatsch L, Morse PA. Evidence-based cognitive rehabilitation: recommendations for clinical practice. Arch Phys Med Rehabil. 2000;81:1596-1615. Review.
94. Gray JM, Robertson I, Pentland B, et al. Microcomputer-based attentional retraining after brain damage: a randomized group controlled trial. Neuropsychol Rehabil. 1992;2:97-115.
95. Niemann H, Ruff RM, Baser CA. Computer-assisted attention retraining in head-injured individuals: a controlled efficacy study of an outpatient program. J Consult Clin Psychol. 1990;58:811-817.
96. Sohlberg MM, Mateer CA. Effectiveness of an attention-training program. J Clin Exp Neuropsychol. 1987;9:117-130.
97. Sohlberg MM, Mateer CA. Training use of compensatory memory books: a three stage behavioral approach. J Clin Exp Neuropsychol. 1989;11:871-891.
98. Strache W. Effectiveness of two modes of training to overcome deficits of concentration. Int J Rehabil Res. 1987;10:141-145.
99. Ryan TV, Ruff RM. The efficacy of structured memory retraining in a group comparison of head trauma patients. Arch Clin Neuropsychol. 1988;3:165-179.
100. Antonucci G, Guariglia C, Judica A, Magnotti L, Paolucci S, Pizzamiglio L, Zoccolotti P. Effectiveness of neglect rehabilitation in a randomized group study. J Clin Exp Neuropsychol. 1995;17:383-389.
101. Beis JM, Andre JM, Baumgarten A, Challier B. Eye patching in unilateral spatial neglect: efficacy of two methods. Arch Phys Med Rehabil. 1999;80:71-76.
102. Fanthome Y, Lincoln NB, Drummond A, Walker MF. The treatment of visual neglect using feedback of eye movements: a pilot study. Disabil Rehabil. 1995;17:413-417.
103. Paolucci S, Antonucci G, Guariglia C, Magnotti L, Pizzamiglio L, Zoccolotti P. Facilitatory effect of neglect rehabilitation on the recovery of left hemiplegic stroke patients: a cross-over study. J Neurol. 1996; 243:308-314.
104. Rossetti Y, Rode G, Pisella L, Farne A, Li L, Boisson D, Perenin MT. Prism adaptation to a rightward optical deviation rehabilitates left hemispatial neglect. Nature. 1998;395:166-169.
105. Wiart L, Come AB, Debelleix X, Petit H, Joseph PA, Mazaux JM, Barat M. Unilateral neglect syndrome rehabilitation by trunk rotation and scanning training. Arch Phys Med Rehabil. 1997;78:424-429.
106. Robinson RG. The Clinical Neuropsychiatry of Stroke. New York: Cambridge University Press; 1998.
107. Tsouna-Hadjis E, Vemmos KN, Zakopoulos N, Stamatelopoulos S. First-stroke recovery process: the role of family social support. Arch Phys Med Rehabil. 2000;81:881-887.
108. Andersen G. Treatment of uncontrolled crying after stroke. Drugs Aging. 1995;6:105-111. Review.
109. Cole MG, Elie LM, McCusker J, Bellavance F, Mansour A. Feasibility and effectiveness of treatments for post-stroke depression in elderly inpatients: systematic review. J Geriatr Psychiatry Neural. 2001;14: 37-41.
110. Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Syst Rev. 2000(4):CD001312.
111. Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after poststroke depression: a double-blind treatment trial. Stroke. 2000; 31:1482-1486.
112. Reding JJ, Orto LA, Winters SW, Fortuna IM, DiPonte P, McDowell FH. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol. 1986;43:763-765.
113. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, Curdue K, Petracca G, Starkstein SE. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000; 157:351-359.
114. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke. 2000;31:1829-1832.
115. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for poststroke emotionalism. Acta Psychiatr Scand. 1998;98:455-458.
116. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry. 1999;14:681-685.
117. Gordon MT. Developing clinical guidelines for the management of patients with stroke. Scottish Intercollegiate Guidelines Network (SIGN). Int J Lang Commun Disord. 1998;33 suppl:152-157.
118. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry. 1993;150:286-293.
119. Reding MJ, Borucki S. Effect of dextroamphetamine on motor recovery after stroke. Neurology. 1995;45(suppl 4):A222. Abstract.
120. Sonde L, Nordstrom M, Nilsson CG, Lokk J, Viitanen M. A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc Dis. 2001;12:253-257.
121. Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines R, Graham SJ, Herrmann N, Szalai JP, Black SE; for the Subacute Therapy with Amphetamine and Rehabilitation for Stroke (STARS) Study Investigators. Physiotherapy coupled with dextroamphetamine for motor rehabilitation after hemiparetic stroke: a randomized controlled trial. In: Program Schedule and Abstracts of the 29th International Stroke Conference. Stroke. 2004;35:239. Abstract No. 23.
122. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil. 1998;79:1047-1050.
123. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001; 358:787-790.
124. Nishino K, Sasaki T, Takahashi K, Chiba M, Ito T. The norepinephrine precursor L-threo-3,4-dihydroxyphenylserine facilitates motor recovery in chronic stroke patients. J Clin Neurosci. 2001;8:547-550.
125. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211-1214.
126. Lazar RM, Fitzsimmons BF, Marshall RS, Mohr JP, Berman MF. Midazolam challenge reinduces neurological deficits after transient ischemic attack. Stroke. 2003;34:794-796.